Cardiff Oncology, Inc. will be hosting a conference call on May 2 at 4:30 p.m. ET/1:30 p.m. PT in San Diego. The clinical-stage biotechnology company, which is leveraging PLK1 inhibition to develop novel therapies across various cancers, announced that it will release its financial results for the first quarter ended March 31, 2024 after the close of trading on May 2.
During the call, Cardiff Oncology will discuss its financial results and provide updates on its clinical programs targeting colorectal cancer, pancreatic cancer, small cell lung cancer, and triple negative breast cancer. Its lead asset is onvansertib, a PLK1 inhibitor that is being evaluated in combination with standard-of-care therapeutics to target tumor vulnerabilities and deliver superior clinical benefit.
Those interested in listening to the live conference call can do so by using the webcast link available in the “Investors” section of Cardiff Oncology’s website. A replay of the call will be available in the investor relations section following its completion on the website. For more information about Cardiff Oncology and their clinical programs, visit their website at
For any questions or media inquiries, please contact James Levine at [jlevine@cardiffoncology] or Grace Spencer from Taft Communications at [grace@taftcommunications]. For investor inquiries, reach out to Kiki Patel from Gilmartin Group at [kiki@gilmartinir].